Immune checkpoint inhibitor (ICPi) therapy used in cancer treatment exerts effect by blocking the actions of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1).1,2 These ICPi drugs have revolutionized oncology and improved survival in patients with advanced melanoma, non–small cell lung cancer, renal cell carcinoma, colorectal, and other cancers
© 2001-2024 Fundación Dialnet · Todos los derechos reservados